IMTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immatics NV (IMTX) is not a strong buy for a beginner investor with a long-term focus at this time. While the technical indicators show some bullish momentum, the financial performance is weak, and there are no significant positive catalysts or trading signals to support immediate investment. The stock's pre-market decline and lack of profitability raise concerns about its near-term potential.
The technical indicators show a mixed picture. The MACD is positive and expanding, suggesting bullish momentum. The RSI is neutral at 53.292, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are at Pivot: 10, R1: 10.424, and S1: 9.576. However, the stock is down -0.99% in pre-market trading, indicating short-term weakness.
Analysts have raised price targets recently, with Mizuho setting a target of $25 and BofA setting a target of $17, indicating optimism about the stock's long-term potential. The company is working on transitioning its PRAME leader into commercial reality, which could drive future growth.
The company reported a FY GAAP EPS of -€1.61 and revenue of €48.2M, reflecting ongoing financial challenges. Revenue dropped significantly by -89.74% YoY in Q3 2025, and the company remains unprofitable. Market sentiment is cautious due to continued losses and lack of profitability.
In Q3 2025, revenue dropped by -89.74% YoY to €5.19M. However, net income improved to -€50.54M, up 489.79% YoY, and EPS increased to -€0.42, up 425% YoY. Despite these improvements, the company remains unprofitable, and its financials indicate significant challenges.
Analysts are optimistic about the stock's long-term potential. Mizuho raised the price target to $25 with an Outperform rating, and BofA raised the target to $17 with a Buy rating. However, there is caution about the sustainability of the biotech sector's recent momentum.
